Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results